<DOC>
	<DOCNO>NCT01356498</DOCNO>
	<brief_summary>This open-label extension phase two double-blind , placebo-controled Phase 3 protocol evaluate PEG-uricase treatment hyperuricemic subject symptomatic gout . The purpose study provide continuation treatment subject complete double-blind study obtain long-term safety efficacy data .</brief_summary>
	<brief_title>Open-Label Extension Study Patients Who Completed Phase 3 Double-blind Study PEG-uricase Symptomatic Gout</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<criteria>Completed treatment one two doubleblind , placebo control study PEGuricase subject hyperuricemia symptomatic gout unstable angina uncontrolled arrhythmia uncontrolled hypertension end stage renal disease require dialysis anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>gout</keyword>
	<keyword>chronic gout</keyword>
</DOC>